KPV and KdPT should not be treated as interchangeable names. A human trial involving one compound does not establish efficacy or safety for the other, even when the two appear in the same discussion of anti-inflammatory peptides.
What the clinical paper actually names
The randomized multicenter ulcerative-colitis study evaluated K(D)PT as an addition to baseline medication. Its abstract describes pooled analyses, a high placebo response and additional analyses. It is not a KPV trial, and its results should not be relabeled as human KPV evidence.
That identity distinction comes before assessing the strength of the result. Even a perfectly conducted trial would answer a question about its own intervention, not a related molecule substituted after publication.
Similar sequences do not establish equivalence
A chemical relationship can motivate comparison, but the comparison still has to be made. Changes in amino-acid identity or configuration may matter to how a molecule behaves. The relevant study should specify what was synthesized and tested rather than relying on a family label.
A primary KPV inflammatory-model paper also illustrates why activity should not simply be inherited from a larger related hormone: the experiment examined how KPV's responses differed from assumptions based on melanocortin receptor activity.
Read claims in the right order
First establish the molecule. Next identify the formulation, population and route. Only then assess the comparator, outcomes, analysis and uncertainty. Starting with a favorable conclusion and working backward makes it easier to overlook an identity mismatch.
For readers investigating gut symptoms, this prevents a common evidence shortcut: citing a related tripeptide's clinical study to bridge KPV's human-data gap. The gap remains unless KPV itself is appropriately studied.
This article does not recommend substituting either compound or borrowing a regimen. It explains why precise naming is a substantive scientific requirement, not a minor editorial preference.